Wu-Mei-Wan promotes ferroptosis in gallbladder cancer through STAT3 negative regulation: An integrated HPLC, proteomics, network pharmacology, and experimental validation study
Journal of Ethnopharmacology · 2025
DOI: 10.1016/j.jep.2025.119671 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Ethnopharmacology, 2025. Verfasst von Jingwei Zhao und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of General Surgery, Xinhua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China; Shanghai Key…. Hauptthemen laut MEDLINE: Ferroptosis, STAT3 Transcription Factor, Gallbladder Neoplasms, Drugs, Chinese Herbal. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China.
Abstract (Originalsprache)
ETHNOPHARMACOLOGICAL RELEVANCE: As a traditional Chinese medicine, Wu-Mei-Wan (WMW) has shown promise as a second-line treatment for gallbladder cancer, but its mechanism remains to be explored. AIM OF THE STUDY: To determine the specific mechanism of WMW active ingredients (Palmatine et al.) inducing ferroptosis in gallbladder cancer (GBC) and its synergistic potential with gemcitabine. MATERIALS AND METHODS: Subcutaneous tumor in nude mice was used to analyze the combined effect of gemcitabine. The effective components into blood were identified by HPLC. Combined with proteomics, network pharmacology and bioinformatics analysis, the effective components and targets of WMW promoting ferroptosis in GBC were identified in vitro and in vivo. The anticancer effects of WMW on different GBC cell lines were evaluated by CCK-8 assay, colony formation and EdU staining. A variety of molecular biology experiments were used to explore the mechanism. RESULTS: WMW treatment enhanced the sensitivity of GBC to gemcitabine, which induced ferroptosis and effectively inhibited the malignant phenotype of GBC. Network pharmacology and blood component identification identified the key components of WMW inhibiting GBC. Palmitine and other components were identified as active components into the blood. Proteomics and molecular docking validation further revealed the STAT3-centered regulatory network in GBC cells. Molecular experiments have shown that WMW induced ferroptosis by negatively regulating downstream molecules of p-STAT3 transcription of GPX4, ACSL4, HIF1α, and FTH1. CONCLUSIONS: WMW induces ferroptosis in GBC through the p-STAT3 axis and enhances sensitivity to gemcitabine, suggesting the potential of WMW as a second-line therapeutic for GBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of General Surgery, Xinhua Hospital, Affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai, 200092, China; Shanghai Key Laboratory of Biliary Tract Disease Research, Shanghai, 200092, China…
Förderung
- National Natural Science Foundation of China
Zitieren
APA
Zhao, J., Shi, L., Yang, Y., Zhu, J., Zhou, Z., Dong, P., Liu, S., Yang, Z., & Gong, W. (2025). Wu-Mei-Wan promotes ferroptosis in gallbladder cancer through STAT3 negative regulation: An integrated HPLC, proteomics, network pharmacology, and experimental validation study. Journal of Ethnopharmacology. https://doi.org/10.1016/j.jep.2025.119671
Vancouver
Zhao J, Shi L, Yang Y, Zhu J, Zhou Z, Dong P, et al. Wu-Mei-Wan promotes ferroptosis in gallbladder cancer through STAT3 negative regulation: An integrated HPLC, proteomics, network pharmacology, and experimental validation study. Journal of Ethnopharmacology. 2025. doi:10.1016/j.jep.2025.119671
BibTeX
@article{Zhao2025,
author = {Zhao, Jingwei and Shi, Liuqing and Yang, Yue and Zhu, Jiayun and Zhou, Zhe and Dong, Ping and Liu, Shilei and Yang, Ziyi and Gong, Wei},
title = {Wu-Mei-Wan promotes ferroptosis in gallbladder cancer through STAT3 negative regulation: An integrated HPLC, proteomics, network pharmacology, and experimental validation study},
journal = {Journal of Ethnopharmacology},
year = {2025},
doi = {10.1016/j.jep.2025.119671}
}
EUVIMED